Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 263 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Nebulizer Clear all
Completed Phase 4 Interventional Results available

Dose-response of Albuterol in Asthmatics

NCT00940927
View directory record Official record
Conditions
Asthma
Interventions
albuterol
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
8 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1994
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 22, 2026, 5:14 PM EDT
Terminated Phase 4 Interventional Results available

Comparison of Nebulizers in ED in Pediatric Asthma Patients

NCT01951378
View directory record Official record
Conditions
Asthma
Interventions
Hudson RCI® nebulizer, NebuTech® HDN® nebulizer, Albuterol
Device · Drug
Lead sponsor
Seton Healthcare Family
Other
Eligibility
3 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 22, 2026, 5:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cough Reflex Sensitivity and Bronchial Hyper-responsiveness

NCT01777867
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Chronic Cough, Broncho-hyperreactivity
Interventions
Cough Reflex Sensitivity, Methacholine Challenge
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label Phase 1 Study of Aerosolized Amikacin and Fosfomycin in Healthy Volunteers

NCT02709265
View directory record Official record
Conditions
Healthy
Interventions
amikacin/fosfomycin
Drug
Lead sponsor
Cardeas Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT03118765
View directory record Official record
Conditions
Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GSP304 (tiotropium bromide) Inhalation Solution, GSP304 Placebo Inhalation Solution, Spiriva® Respimat® inhalation spray
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
40 Years to 85 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
25
States / cities
Andalusia, Alabama • Phoenix, Arizona • Tempe, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Not applicable Interventional Results available

Aerosolized Albuterol Use in Severe BPD

NCT02766673
View directory record Official record
Conditions
Severe Bronchopulmonary Dysplasia
Interventions
Albuterol Sulfate, Sterile Saline
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 1 Year
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 22, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection

NCT06999603
View directory record Official record
Conditions
Viral Pneumonia
Interventions
SNG001, Placebo
Drug
Lead sponsor
Synairgen Research Ltd.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 22, 2026, 5:14 PM EDT
Active, not recruiting Phase 4 Interventional

The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)

NCT06152653
View directory record Official record
Conditions
Asthma, COPD
Interventions
n-acetylcystine (NAC)+ albuterol, AeroEclipse-VersaPAP System
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Use of ARINA-1 in an Intermediate Size Patient Population of Bilateral Lung Transplant Patients With CLAD Grade 0

NCT03226431
View directory record Official record
Conditions
Lung Transplant
Interventions
Ascorbic Acid
Drug
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 22, 2026, 5:14 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

NCT04544293
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Molgramostim, Placebo, Molgramostim Open-label
Drug
Lead sponsor
Savara Inc.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
16
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung

NCT00006483
View directory record Official record
Conditions
Kidney Cancer, Metastatic Cancer
Interventions
sargramostim
Biological
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
22
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection

NCT01924793
View directory record Official record
Conditions
Parainfluenza
Interventions
DAS181-F02 Dry Powder in Bulk, DAS181-F02 Nebulized Formulation Inhaled Dose
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
12 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
23
States / cities
Duarte, California • Orange, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 22, 2026, 5:14 PM EDT
Active, not recruiting No phase listed Observational

Clinical Markers of Dysphagia in Cardiac Surgical Patients

NCT05304416
View directory record Official record
Conditions
Cardiovascular Diseases, Dysphagia
Interventions
Fiberoptic Endoscopic Evaluation of Swallowing, Simultaneous FEES and Videofluoroscopy instrumental swallowing exam, Videofluoroscopy instrumental swallowing exam (VFSS), Voluntary Cough Peak Expiratory Flow (PEF) Testing, Reflex Cough Screen, Lingual Pressure Testing, Speech Testing
Diagnostic Test · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Gainesville, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 22, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection

NCT03597347
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF)
Interventions
Molgramostim nebulizer solution, PARI eFlow nebulizer system
Drug · Device
Lead sponsor
Savara Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Denver, Colorado • Orlando, Florida • New Hyde Park, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 22, 2026, 5:14 PM EDT
Recruiting Phase 4 Interventional

Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators

NCT07133880
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ), Placebo DPI
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
40 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 5:14 PM EDT
Not yet recruiting Not applicable Interventional

Improving the Quality of Care for Asthma Patients at Risk of Exacerbations

NCT06596512
View directory record Official record
Conditions
Asthma, Asthma Chronic, Asthma Severe Persistent With Exacerbation, Asthma Moderate Persistent With Exacerbation
Interventions
PARTICS using a single ICS add on, MART
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
4,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
New Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD

NCT02038829
View directory record Official record
Conditions
COPD
Interventions
Placebo, SUN101 3 mcg, SUN-101 6.25 mcg, SUN-101 12.5 mcg, SUN-101 50 mcg, Aclidinium
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
10
States / cities
Clearwater, Florida • Charlotte, North Carolina • Raleigh, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Iloprost in Preventing Lung Cancer in Former Smokers

NCT02237183
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Iloprost, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects

NCT01409122
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
15 mg sodium nitrite inhalation solution, 90 mg sodium nitrite inhalation solution, 45 mg sodium nitrite inhalation solution, 120 mg sodium nitrite inhalation solution, 25% MTD sodium nitrite inhalation solution
Drug
Lead sponsor
Aires Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 56 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2012 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01706536
View directory record Official record
Conditions
COPD
Interventions
Placebo, EP-101 12.5 mcg, EP-101 25 mcg, EP-101 50 mcg, EP-101 100 mcg
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
35 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
26
States / cities
Jasper, Alabama • Phoenix, Arizona • Fullerton, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Oct 22, 2026, 5:14 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers

NCT07644195
View directory record Official record
Conditions
Healthy Volunteer
Interventions
TRL1068, a human monoclonal antibody
Drug
Lead sponsor
Trellis Bioscience LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

NCT01641822
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI, Placebo to match AZLI, Tobramycin inhalation solution
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 62 more
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

NCT01314716
View directory record Official record
Conditions
Bronchiectasis
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Florence, Alabama • Flagstaff, Arizona • Peoria, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 22, 2026, 5:14 PM EDT